ArticleMolecular neurobiology2017
miR-124 Acts as a Tumor Suppressor in Glioblastoma via the Inhibition of Signal Transducer and Activator of Transcription 3.
Article in Molecular neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The significance of miR-124 in the diagnosis and prognosis of glioma: A systematic review.PloS one · 2024Pooled it
- MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways.Cell cycle (Georgetown, Tex.) · 2019Article
- The effect of miR-124-3p on cell proliferation and apoptosis in bladder cancer by targeting EDNRB.Archives of medical science : AMS · 2019Article
- MicroRNA-124: An emerging therapeutic target in cancer.Cancer medicine · 2019Review
- Hypermethylation-mediated inactivation of miR-124 predicts poor prognosis and promotes tumor growth at least partially through targeting EZH2/H3K27me3 in ESCC.Clinical & experimental metastasis · 2019Article
- p62 acts as an oncogene and is targeted by miR-124-3p in glioma.Cancer cell international · 2019Article
- miR‑203 contributes to pre‑eclampsia via inhibition of VEGFA expression.Molecular medicine reports · 2018Article
- Influence of SIRT6 regulation of cellular glycometabolism on radiosensitivity of non-small-cell lung cancer A549 cells.International journal of clinical and experimental pathology · 2018Article
- MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma.BioMed research international · 2017Review
- MicroRNA-124-3p affects proliferation, migration and apoptosis of bladder cancer cells through targeting AURKA.Cancer biomarkers : section A of Disease markers · 2017Article
- The role of IL-10 in Mycobacterium avium subsp. paratuberculosis infection.Cell communication and signaling : CCS · 2016Review
- Role of microRNAs in inflammation-associated liver cancer.Cancer biology & medicine · 2016Article
- miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1.Oncotarget · 2016Article
- miR-204 suppresses the development and progression of human glioblastoma by targeting ATF2.Oncotarget · 2016Article
Corrections and comments
- Retraction · 2017-07-13False/Forged Authorship · Compromised Peer Review · Plagiarism of/in Article · · RW link is for related story - not of article itself.
- Retracted
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs are important regulators of multiple cellular processes, and aberrant miRNA expression has been observed in human glioblastoma (GBM). The present study was to evaluate the level of miR-124 and signal transducer and activator of transcription 3 (STAT3) in GBM tissues and cells. We further investigated the molecular mechanisms of miR-124 and STAT3 in GBM cell lines U87 and U251. Here, we found that miR-124 expression was downregulated in GBM tissues and U87 and U251 cells (all p < 0.001) but not associated with blood routine (RBC, WBC count, etc.) and liver and renal function indicators (all p > 0.05). By contrast, STAT3 was upregulated. Furthermore, the expression of miR-124 was inversely proportional to that of STAT3 mRNA or protein (p = 0.013, p = 0.015, respectively). In vitro studies demonstrated that the overexpression of miR-124 played a suppressor role in the proliferation of U87 and U251 cells and promoted cell apoptosis. Luciferase reporter assays confirmed that miR-124 binding to the 3'-UTR regions of STAT3 inhibited the expression of STAT3 in U87 and U251 cells. However, the inhibitor of miR-124 promoted the expression of STAT3 and cell proliferation. In conclusion, our data suggest that miR-124 may have a potential role in treatment of GBM patients and that miR-124 is a novel regulator of invasiveness and tumorigenicity in GBM cells by targeting STAT3. The miR-124/STAT3 pathway may be a useful therapeutic agent in GBM patients.
Indexed as
Identifiers
26993295What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.